<p>Glenmark on Wednesday announced the launch of its nasal spray for Covid-19 treatment under the brand name Fabispray.</p>.<p>Fabispray, which is developed by the company along with its Canada-based partner SaNOtize Research & Development Corp, will be available in India at Rs 850 for adult patients who possess a high risk of progression of the Covid-19 disease.</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/science-and-environment/possibility-of-new-covid-19-variants-really-high-says-who-technical-lead-maria-van-kerkhove-1079790.html" target="_blank">Possibility of new Covid-19 variants really high, says WHO Technical Lead Maria Van Kerkhove</a></strong></p>.<p>Fabispray must be used after a prescription from a registered medical practitioner. The recommended dosage of the Nitric Oxide Nasal Spray (NONS) is two sprays at once, six times a day for 7 days. </p>.<p>"The pricing of Fabispray is nominal in India compared to other countries," Dr. Monika Tandon, head of clinical development at Glenmark, <a href="http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-to-sell-nasal-spray-for-covid-care-for-850/articleshow/89466384.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst" target="_blank">told </a>by <em>The Economic Times.</em></p>.<p>The spray has reportedly been designed to kill the coronavirus in the upper airways to prevent it from incubating spreading to the lungs.</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/science-and-environment/vaccine-protection-better-maintained-against-severe-covid-19-lancet-study-1079303.html" target="_blank">Vaccine protection better maintained against severe Covid-19: Lancet study</a></strong></p>.<p>"It is based on nitric oxide, which has proven anti-microbial properties and a direct effect on SARS-CoV-2," Tandon said.</p>.<p>According to Tandon, the phase 3 clinical trial of Fabispray was conducted in adult Covid-19 patients from over 20 clinical sites throughout the country, The double-blind, parallel-arm and multicenter studies were conducted in 306 patients.</p>.<p>The study looked at non-vaccinated patients, patients in their middle and older years, and patients with comorbidities who were at risk of disease progression.</p>.<p>The study's primary endpoint was fulfilled, Glenmark said. The NONS group had a statistically significant reduction in viral load compared to the control (placebo) group.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>
<p>Glenmark on Wednesday announced the launch of its nasal spray for Covid-19 treatment under the brand name Fabispray.</p>.<p>Fabispray, which is developed by the company along with its Canada-based partner SaNOtize Research & Development Corp, will be available in India at Rs 850 for adult patients who possess a high risk of progression of the Covid-19 disease.</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/science-and-environment/possibility-of-new-covid-19-variants-really-high-says-who-technical-lead-maria-van-kerkhove-1079790.html" target="_blank">Possibility of new Covid-19 variants really high, says WHO Technical Lead Maria Van Kerkhove</a></strong></p>.<p>Fabispray must be used after a prescription from a registered medical practitioner. The recommended dosage of the Nitric Oxide Nasal Spray (NONS) is two sprays at once, six times a day for 7 days. </p>.<p>"The pricing of Fabispray is nominal in India compared to other countries," Dr. Monika Tandon, head of clinical development at Glenmark, <a href="http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-to-sell-nasal-spray-for-covid-care-for-850/articleshow/89466384.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst" target="_blank">told </a>by <em>The Economic Times.</em></p>.<p>The spray has reportedly been designed to kill the coronavirus in the upper airways to prevent it from incubating spreading to the lungs.</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/science-and-environment/vaccine-protection-better-maintained-against-severe-covid-19-lancet-study-1079303.html" target="_blank">Vaccine protection better maintained against severe Covid-19: Lancet study</a></strong></p>.<p>"It is based on nitric oxide, which has proven anti-microbial properties and a direct effect on SARS-CoV-2," Tandon said.</p>.<p>According to Tandon, the phase 3 clinical trial of Fabispray was conducted in adult Covid-19 patients from over 20 clinical sites throughout the country, The double-blind, parallel-arm and multicenter studies were conducted in 306 patients.</p>.<p>The study looked at non-vaccinated patients, patients in their middle and older years, and patients with comorbidities who were at risk of disease progression.</p>.<p>The study's primary endpoint was fulfilled, Glenmark said. The NONS group had a statistically significant reduction in viral load compared to the control (placebo) group.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>